Google Secures Pentagon AI Deal for Classified Projects 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
MENLO PARK, Calif., Feb. 10, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the RBC Capital Markets 2016 Global Healthcare Conference in New York at 8:30 a.m. Eastern Time on Tuesday, February 23.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://www.veracast.com/webcasts/rbc/healthcare2016/04102457748.cfm. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
